1). Cooper DK. A brief history of cross-species organ transplantation. Proc (Bayl Univ Med Cent). 2012. 25:49–57.
Article
2). Gugenheim J., Samuel D., Reynes M., Bismuth H. Liver transplantation across ABO blood group barriers. Lancet. 1990. 336:519–23.
Article
3). Usuda M., Fujimori K., Koyamada N., Fukumori T., Sekiguchi S., Kawagishi N, et al. Successful use of anti-CD20 mono-clonal antibody (rituximab) for ABO-incompatible living-related liver transplantation. Transplantation. 2005. 79:12–6.
Article
4). Egawa H., Teramukai S., Haga H., Tanabe M., Fukushima M., Shimazu M. Present status of ABO-incompatible living donor liver transplantation in Japan. Hepatology. 2008. 47:143–52.
Article
5). Demetris AJ., Bellamy C., Hubscher SG., O'Leary J., Randhawa PS., Feng S, et al. 2016 Comprehensive update of the Banff Working Group on liver allograft pathology: introduction of antibody-mediated rejection. Am J Transplant. 2016. 16:2816–35.
6). Krishnan NS., Zehnder D., Briggs D., Higgins R. Human leukocyte antigen antibody incompatible renal transplantation. Indian J Nephrol. 2012. 22:409–14.
Article
7). Song GW., Lee SG., Hwang S., Kim KH., Ahn CS., Moon DB, et al. ABO-incompatible adult living donor liver transplantation under the desensitization protocol with rituximab. Am J Transplant. 2016. 16:157–70.
Article
8). Castillo-Rama M., Castro MJ., Bernardo I., Meneu-Diaz JC., Elola-Olaso AM., Calleja-Antolin SM, et al. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: role of human leukocyte antigen compatibility. Liver Transpl. 2008. 14:554–62.
Article
9). Kozlowski T., Rubinas T., Nickeleit V., Woosley J., Schmitz J., Collins D, et al. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl. 2011. 17:357–68.
Article
10). O'Leary JG., Kaneku H., Jennings LW., Banuelos N., Susskind BM., Terasaki PI, et al. Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation. Liver Transpl. 2013. 19:973–80.
11). Taner T., Gandhi MJ., Sanderson SO., Poterucha CR., De Goey Sr., Stegall MD, et al. Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant. 2012. 12:1504–10.
Article
12). Kaneku H., O'Leary JG., Banuelos N., Jennings LW., Susskind BM., Klintmalm GB, et al. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant. 2013. 13:1541–8.
13). Zou Y., Heinemann FM., Grosse-Wilde H., Sireci G., Wang Z., Lavingia B, et al. Detection of anti-MICA antibodies in patients awaiting kidney transplantation, during the post-transplant course, and in eluates from rejected kidney allografts by Luminex flow cytometry. Hum Immunol. 2006. 67:230–7.
Article
14). Alten TA., Negm AA., Voigtlander T., Jaeckel E., Lehner F., Brauner C, et al. Safety and performance of liver biopsies in liver transplant recipients. Clin Transplant. 2014. 28:585–9.
Article
15). O'Leary JG., Kaneku H., Demetris AJ., Marr JD., Shiller SM., Susskind BM, et al. Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss. Liver Transpl. 2014. 20:218–27.